🕵️ Olema Pharmaceuticals, Inc. ($OLMA)
SEC insider & ownership activity, last 12 months · CIK 1750284 · every row links its SEC filing
Over the last 12 months insiders sold $24.9M with no open-market buying against it. Ian T. Clark sold $7.9M in discretionary trades (Dec). 1 planned sale is pending, the largest $145K (Harmon Cyrus). No red-flag 8-Ks in the window.
🚨 7 signals active —
planned-vs-executed verdicts, pre-event flags, and cluster context live in the
API and the
alerts bot.
Monthly net open-market insider flow, last 12 months (up = net buying)
Insider flow
0 buyers, $0 (0 lots) · 6 sellers, $24.9M (29 lots)
| Insider | Buys | Bought | Sells | Sold | Last |
|---|---|---|---|---|---|
| Ian T. Clark | 0 | – | 3 | $7.9M | Dec 19, 2025 |
| Zojwalla Naseem | 0 | – | 4 | $7.5M | Dec 23, 2025 |
| David C. Myles | 0 | – | 8 | $4.7M | Jan 14, 2026 |
| Kovacs Shane William Charles | 0 | – | 2 | $3.0M | Jan 15, 2026 |
| Mitchell Shawnte | 0 | – | 3 | $952K | Mar 4, 2026 |
| Harmon Cyrus | 0 | – | 9 | $949K | Jul 24, 2026 |
5%+ holders
| Holder | Stake | Class | Schedule | Event | |
|---|---|---|---|---|---|
| FMR LLC | 12.5% | 13G | Mar 6, 2026 | filing ↗ | |
| Abigail P. Johnson | 12.5% | 13G | Mar 6, 2026 | filing ↗ | |
| Paradigm Biocapital Advisors LP | 10.0% | 13G | Feb 14, 2025 | filing ↗ | |
| Paradigm Biocapital Advisors GP LLC | 10.0% | 13G | Feb 14, 2025 | filing ↗ | |
| Senai Asefaw, M.D. | 10.0% | 13G | Feb 14, 2025 | filing ↗ | |
| Paradigm Biocapital International Fund Ltd. | 9.1% | 13G | Feb 14, 2025 | filing ↗ | |
| Janus Henderson Group PLC | 8.2% | 13G | May 15, 2026 | filing ↗ | |
| BAIN Capital Life Sciences Opportunities IV, L.P. | 8.2% | 13G | May 15, 2026 | filing ↗ | |
| Blackrock, Inc. | 7.1% | 13G | Jul 29, 2026 | filing ↗ | |
| Raymond Debbane | 5.1% | 13G | Mar 20, 2026 | filing ↗ |
Planned insider sales (Form 144)
| Seller | Planned | Approx. sale date | |
|---|---|---|---|
| Harmon Cyrus | $146K | Jul 24, 2026 | filing ↗ |
| Harmon Cyrus | $145K | Jul 23, 2026 | filing ↗ |
| Kovacs Shane William Charles | $69K | Mar 16, 2026 | filing ↗ |
| Kovacs Shane William Charles | $1.6M | Mar 16, 2026 | filing ↗ |
| Kovacs Shane William Charles | $797K | Mar 11, 2026 | filing ↗ |
| Kovacs Shane William Charles | $905K | Mar 10, 2026 | filing ↗ |
| Kovacs Shane William Charles | $3.3M | Mar 9, 2026 | filing ↗ |
| Kovacs Shane William Charles | $489K | Mar 4, 2026 | filing ↗ |
| Mitchell Shawnte | $598K | Mar 4, 2026 | filing ↗ |
| Mitchell Shawnte | $345K | Mar 3, 2026 | filing ↗ |
| Kovacs Shane William Charles | $163K | Feb 27, 2026 | filing ↗ |
| Kovacs Shane William Charles | $500K | Feb 24, 2026 | filing ↗ |
| Kovacs Shane William Charles | $243K | Feb 23, 2026 | filing ↗ |
| Kovacs Shane William Charles | $480K | Feb 23, 2026 | filing ↗ |
| Kovacs Shane William Charles | $238K | Feb 12, 2026 | filing ↗ |
| Harmon Cyrus | $269K | Jan 20, 2026 | filing ↗ |
| Kovacs Shane William Charles | $2.9M | Jan 15, 2026 | filing ↗ |
| Harmon Cyrus | $102K | Jan 14, 2026 | filing ↗ |
| David C. Myles | $1.4M | Jan 14, 2026 | filing ↗ |
| Kovacs Shane William Charles | $107K | Jan 13, 2026 | filing ↗ |
| David C. Myles | $1.4M | Jan 13, 2026 | filing ↗ |
| David C. Myles | $283K | Jan 12, 2026 | filing ↗ |
| Zojwalla Naseem | $2.8M | Dec 23, 2025 | filing ↗ |
| Harmon Cyrus | $82K | Dec 22, 2025 | filing ↗ |
| Zojwalla Naseem | $2.8M | Dec 22, 2025 | filing ↗ |
| David C. Myles | $1.6M | Dec 19, 2025 | filing ↗ |
| Zojwalla Naseem | $2.0M | Dec 19, 2025 | filing ↗ |
| Ian T. Clark | $7.9M | Dec 19, 2025 | filing ↗ |
| Harmon Cyrus | $109K | Sep 18, 2025 | filing ↗ |
| Harmon Cyrus | $96K | Sep 16, 2025 | filing ↗ |
Material events (8-K)
| Item | Event date | |
|---|---|---|
| Shareholder vote (5.07) | Jun 17, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | May 26, 2026 | filing ↗ |
| Other events (8.01) | May 26, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | May 26, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | May 21, 2026 | filing ↗ |
| Other events (8.01) | May 21, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | May 21, 2026 | filing ↗ |
| Earnings (2.02) | May 12, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | May 12, 2026 | filing ↗ |
| Material agreement (1.01) | Apr 27, 2026 | filing ↗ |
| New financial obligation (2.03) | Apr 27, 2026 | filing ↗ |
| Officer/director changes (5.02) | Apr 27, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Apr 27, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Apr 27, 2026 | filing ↗ |
| Earnings (2.02) | Mar 16, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Mar 16, 2026 | filing ↗ |
| Officer/director changes (5.02) | Jan 27, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jan 27, 2026 | filing ↗ |
| Earnings (2.02) | Jan 12, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Jan 12, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jan 12, 2026 | filing ↗ |
| Other events (8.01) | Nov 19, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Nov 19, 2025 | filing ↗ |
| Other events (8.01) | Nov 18, 2025 | filing ↗ |
| Earnings (2.02) | Nov 10, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Nov 10, 2025 | filing ↗ |
| Reg FD disclosure (7.01) | Oct 18, 2025 | filing ↗ |
| Other events (8.01) | Oct 18, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Oct 18, 2025 | filing ↗ |
| Reg FD disclosure (7.01) | Sep 2, 2025 | filing ↗ |